c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
about
Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancerErk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancerFunctional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancerCombining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRKBrk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factorc-Src-null mice exhibit defects in normal mammary gland development and ERalpha signalingExpression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferationUse of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.Role of HER2 gene overexpression in breast carcinoma.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancerThe biology of mammary transgenes: five rules.ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependencyAdenovirus-directed expression of Q227L-G alpha(s) inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice.Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.HER2: the neu prognostic marker for breast cancer.Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.The significance of immunohistochemistry in the diagnosis and therapy of neoplasms.Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cellsNonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers.Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 statusIHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Targeted therapy in breast cancer: the HER-2/neu gene and protein.Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T genePrognostic significance of c-erbB-2 expression in node negative breast cancerHormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.Prostatic carcinoma: a multivariate analysis of prognostic factors.The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.Expression of the ERBB3 gene product in breast cancer.Association between hormone receptors and HER-2/neu is age-relatedPrognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates.
P2860
Q24315647-6E2836DC-EF97-4DD6-83E7-84EC71DA2B95Q24318999-5A62FA80-B032-4148-B85E-8809FDDB8668Q24538180-FDC029A7-BD29-4F90-A918-6CF631A82D8FQ24609066-385233D2-39C7-41C7-A403-A1168DC558C7Q24813543-01D91DCA-0BD3-4E02-B6EE-B625A9C66978Q25257296-084C9FCD-86A2-4B78-B271-65192D38CE49Q27824846-5D24CE56-1054-4333-ABA6-5E17A9DE51CDQ28138242-B93DB8A9-C678-47B9-ACB4-166820CF4B9CQ28298083-BE1DDBBF-E575-4A94-B6E0-F6D9A00BF466Q28504741-C6C13C1C-2515-401A-944D-82E9276FC49DQ28570541-0F3A36FD-CAA7-4681-A6C1-C549728AA8A8Q28678895-AAB57FA8-0609-4469-90DF-D6470ACEDEC4Q33596695-B2529237-0875-44DD-AF85-D36764253952Q33810080-9EDCF51D-3068-48A9-9A23-F4E6732445C6Q33890758-934422E5-6E9B-4C4E-9B86-F110BB3054A3Q33962717-121DBCCD-BF6E-4B00-B9C9-558B04AF1317Q33963261-E17AFD63-6517-481F-BADB-B0B534F876CBQ34010590-30110C43-4B67-4DAC-8436-4A82D627176DQ34166938-8B548EE2-FBBB-42FB-B0A9-2B49CCC393E1Q34248406-34EAB37B-F940-4A28-AA05-2ACFC821F2CEQ34255976-0AF0807B-5DA4-487E-8E9D-B3E447534E28Q34602545-28F91730-2D9C-45FC-8FEE-AFBF84B2F494Q34674715-0073CD85-0F7B-41AF-9C24-08579976ABC9Q34912810-CF405AA0-A48D-4B82-9DF0-4900778B8563Q35036351-086C3361-F3EE-4F44-9A99-C62DC198CE27Q35234774-6F9026F7-D9D2-4D6B-B977-7B3E38E473A4Q35367235-98AF9D7F-0F29-40E7-826F-D454A2A9CCA0Q35583711-1351E243-D35D-4363-8DCC-0FFA795C24EFQ35588768-FEF9985C-D0EB-4F3C-B7FC-21D6496E5AFFQ35648508-7E2CB146-54B1-4AA4-BE86-9B39F1C600CEQ35782155-C2C14D58-B62F-4611-BEB2-B5394C61F0CCQ35976044-8EB46F04-6C86-49D9-8A27-31A136E45B64Q35977233-FB9D4513-BB46-470E-820A-E8A3FC8E25ECQ35978450-018406BD-368B-44B9-BD9F-7549B1807896Q35988844-8E686183-594D-492A-9205-7765482287E7Q35993223-6C4A4322-9684-4E67-A1A8-5A5AEF88B597Q35994633-6583F40A-CF27-4111-A024-A5BDBC4CB51AQ36014465-BADC14EC-9366-4C54-993B-BC2E14F7D5C9Q36080594-E44470A0-606B-4666-89D1-68EAC0B011A9Q36081172-DA7E0EA8-39A0-4E34-A071-44E69203D54B
P2860
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@ast
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@en
type
label
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@ast
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@en
prefLabel
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@ast
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@en
P2093
P2860
P921
P356
P1476
c-erbB-2 protein overexpressio ...... ed and uninvolved lymph nodes.
@en
P2093
Gullick WJ
Gusterson B
P2860
P2888
P304
P356
10.1038/BJC.1991.100
P407
P577
1991-03-01T00:00:00Z
P5875
P6179
1033946005